A375 Transfection Reagent (Melanoma Cells, CRL-1619)

In this study, researchers test the anti-tumor effects of combined IL-24/OSM adenoviral-mediated tumor suppressor gene co-transfer in A375 cells. Interleukin-24 (IL-24) is a cytokine-tumor suppressor that exhibits anti-tumor properties. Oncostatin M (OSM) inhibits the proliferation of various solid tumor cell lines. Researchers combined IL-24 and OSM to form a bicistronic adenovirus and tested its effect on A375 cells in vivo and in vitro . Results indicate that IL-24/OSM reduces certain protein expressions in A375 cell cycles and this activity is closely associated with the activation of an apoptotic pathway and inhibition of tumor angiogenesis. Therefore, combining two or more tumor suppressors may lead to a new strategy of treating melanoma. [ LINK ] An  A375 Transfection Reagent  is commercially available from  Altogen Biosystems , which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found  here .

Bufotalin, an active component of Venenum bufonis, has long been used as an anti-tumor drug in China and has proven anti-tumor effects in cancer types. In the following study, researchers use MTT and colony formation assays to analyze the effects of bufotalin on A375 melanoma cells. Results show that bufotalin induces A375 cell cycle arrest at the G2/M phase by up-regulating and down-regulating specific protein expressions. Furthermore, bufotalin up-regulates apoptosis-related proteins, in turn inducing A375 cell apoptosis. These results indicate that bufotalin may prove effective in melanoma treatment. [ LINK ] An  A375 Transfection Reagent  is commercially available from  Altogen Biosystems , which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found  here .

In the following study, researchers test the effect of microRNA-183 (miR-183) on A375 melanoma cells. Lentiviral transfection was used to construct an A375 cell line with stable miR-183 over-expression or knockdown. Additionally, r everse transcription-quantitative polymerase chain reaction was used to measure the change of miR-183 expression in A375 cells, and  a scratch and Transwell assay was used to determine its effects on A375 cell migration. Results show that miR-183 expression inhibits A375 migration and invasiveness. This effect is supported by the fact that  Ezrin and MMP-9, two known promoters of melanoma metastasis, are revealed to be negatively regulated by miR-183. Therefore, miR-183 may inhibit A375 melanoma cell migration by targeting and inhibiting Ezrin and MMP-9 expression. This study may ultimately contribute novel insights to the development of anti-metastasis gene therapy. [ LINK ] An  A375 Transfection Reagent  is commercially available from  Altogen Biosystems

Sutherlandia frutescens is a plant native to Southern Africa that has been traditionally used for treating various ailments and even reported to have anticancer activity. Based on claims of anticancer activity, the plant has been locally dubbed the "cancer bush".  Sutherlandia frutescens is commercially available in the form of tablets or tinctures and consuming the product is not associated with any toxic side effects. In the following study, scientists research the effect of  Sutherlandia frutescens on A375 melanoma cells. The aim of the study is to find evidence of whether or not the plant extract induces apoptosis on the A375 melanoma cell line. Results show that  Sutherlandia frutescens is cytotoxic in a dose- and time-dependent manner and induces caspase-dependent and caspase-independent apoptosis in A375 cells. Gene analysis conducted during the study also molecular targets the  Sutherlandia frutescens extract, which include:  angiogenesis, metastasis, EMT (epithelial-

A375 cells have been used as test organisms that also produce paracrine factors for prolonged culture of mesenchymal stromal cells (MSCs). Melanoma is the most lethal formal of skin cancer and is responsible for more than 75% of skin cancer-related deaths. The A375 cell line is relevant to melanoma studies, and it was originally obtained from a 54-year-old female. A375 cells are epithelial-like with adherent properties, hypotriploid, and have a modal number of 62 chromosomes. The cells produce large amounts of amelanotic melanomas in xenografts of NIH swiss mice treated with anti-thymocyte serum. A375 cells are suitable for transfection applications, especially those that deal with oncogenetic factors that are tied to melanomas. For the A375 transfection reagent , visit the Altogen Biosystems website.

Altogen Biosystems is a ­current global provider of transfection reagents and contract research services for researchers in gene-related fields. Some of the services that are offered include assay development, fast generation of stably-transfected cell lines, and other laboratory services including siRNA screening. For an A375 cell xenograft model  and other valuable resources visit the Altogen Biosystems website.